How should ezetimibe be initiated, and what are its indications, contraindications, and monitoring requirements?

Ezetimibe: Initiation, Indications, Contraindications, and Monitoring

Initiate ezetimibe at 10 mg orally once daily, with or without food, as add-on therapy to maximally tolerated statin when LDL-C remains above goal, or as monotherapy when statins cannot be used.

Indications

Primary indication: Add ezetimibe to statin therapy when LDL-C targets are not achieved on maximally tolerated statin alone 1, 2.

Risk-Stratified Approach:

• Very high cardiovascular risk patients (ASCVD, recent ACS): Add ezetimibe when LDL-C remains ≥70 mg/dL (1.8 mmol/L) on maximally tolerated statin 3
• High cardiovascular risk patients: Add ezetimibe when LDL-C goals (typically <100 mg/dL) are not met with statin alone 3
• Primary prevention in patients ≥75 years: Consider ezetimibe monotherapy as an alternative to statins, particularly when statin intolerance or adverse effects are concerns 4

FDA-Approved Indications 2:

• Primary hyperlipidemia (including heterozygous familial hypercholesterolemia) - as adjunct to statin or alone when additional LDL-C lowering is needed
• Mixed hyperlipidemia - in combination with fenofibrate
• Homozygous familial hypercholesterolemia - in combination with statin and other LDL-C lowering therapies
• Homozygous familial sitosterolemia - as adjunct to diet
• Pediatric patients ≥10 years with HeFH (in combination with statin)

Dosing and Administration

Standard dose: 10 mg once daily 1

• Can be taken morning or evening
• With or without food
• Critical timing: Take ≥2 hours before or ≥4 hours after bile acid sequestrants (cholestyramine) to avoid reduced absorption 1

Special population - cyclosporine coadministration: Start at 5 mg daily and titrate upward with careful monitoring, as cyclosporine increases ezetimibe exposure 2.3- to 12-fold 5, 6

Expected LDL-C Reduction

• Monotherapy: 17-20% reduction 1
• Added to statin: Additional 25% incremental reduction (18% placebo-corrected) 1
• Combination with bempedoic acid plus statin: 38% reduction 1

Contraindications

Absolute contraindications 2:

• Known hypersensitivity to ezetimibe (anaphylaxis, angioedema, rash, urticaria have been reported)
• When used with statin, fenofibrate, or other LDL-C lowering therapy: any contraindication to those agents applies

Relative contraindications:

• Moderate to severe hepatic impairment 1

Warnings and Precautions

Hepatic Monitoring 1:

• Monitor hepatic transaminases before and during treatment when combined with statin, following statin monitoring recommendations
• Not recommended in moderate/severe hepatic impairment

Myopathy Risk 1:

• Cases of myopathy and rhabdomyolysis reported when used alone or with statins
• Monitor for muscle pain, tenderness, or weakness
• Common pitfall: Assuming ezetimibe is completely free of muscle-related adverse effects—13.9% of patients experience muscle-related symptoms 7

Renal Considerations:

• No dose adjustment needed for mild-to-severe renal insufficiency 8
• Patients with CKD may experience greater LDL-C reductions (27% vs 23.5% in non-CKD patients) without increased muscle-related adverse effects 7

Drug Interactions

Significant Interactions 1, 8:

Bile acid sequestrants (cholestyramine):

• Significantly decreases ezetimibe bioavailability
• Management: Separate administration by ≥2 hours before or ≥4 hours after ezetimibe

Cyclosporine:

• Increases ezetimibe exposure 2.3- to 12-fold
• Ezetimibe also increases cyclosporine levels
• Management: Start ezetimibe at 5 mg daily; monitor cyclosporine levels closely 5

Fibrates (gemfibrozil, fenofibrate):

• Increase ezetimibe bioavailability
• Clinical significance considered minor due to flat dose-response curve 8

Statins with dose restrictions when combined with bempedoic acid:

• Avoid simvastatin >20 mg daily
• Avoid pravastatin >40 mg daily 1

No clinically significant interactions with 8:

• Other statins (atorvastatin, fluvastatin, lovastatin, rosuvastatin)
• Digoxin, glipizide, warfarin
• Oral contraceptives
• Antacids, cimetidine

Monitoring Requirements

Baseline Assessment:

• Lipid panel (LDL-C, non-HDL-C, total cholesterol)
• Hepatic transaminases (if combining with statin)
• Assess for muscle symptoms

Follow-up Monitoring:

Lipid monitoring:

• Recheck lipid panel at 2 weeks (when maximal LDL-C reduction occurs) 6
• Then at 3 months to assess goal achievement
• Periodically thereafter per guideline recommendations

Hepatic monitoring:

• Follow statin monitoring recommendations when used in combination 1
• Monitor for signs/symptoms of hepatotoxicity

Muscle monitoring:

• Assess for muscle pain, tenderness, weakness at each visit
• No routine CK monitoring required unless symptomatic

Special monitoring with cyclosporine:

• Monitor cyclosporine levels closely
• More frequent lipid monitoring given enhanced ezetimibe exposure 5

Pregnancy and Lactation

Avoid use during pregnancy - no safety data in humans 1, 2

Cardiovascular Outcomes Evidence

IMPROVE-IT trial: Ezetimibe added to moderate-intensity statin in post-ACS patients reduced major cardiovascular events over 6 years 1

SHARP trial: Simvastatin plus ezetimibe reduced major ASCVD events in CKD patients over 4.9 years 1

EWTOPIA 75: Ezetimibe monotherapy reduced ASCVD events in patients ≥75 years without prior CAD 4

Clinical Pearls

• Generally well tolerated with safety profile similar to placebo in most patients 6
• Generic available - cost-effective option 1
• Particularly beneficial in elderly patients (≥75 years) where cholesterol absorption efficiency increases with age 4
• May allow use of lower statin doses to achieve equivalent LDL-C reduction, reducing statin-related adverse effects 9
• Common pitfall: Forgetting to separate administration from bile acid sequestrants, resulting in treatment failure